Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Serengulam V. Govindan, Robert M. Sharkey & David M. Goldenberg. (2016) Prospects and progress of antibody-drug conjugates in solid tumor therapies. Expert Opinion on Biological Therapy 16:7, pages 883-893.
Read now
Read now
Christine Sedlik, Adèle Heitzmann, Sophie Viel, Rafik Ait Sarkouh, Cornélie Batisse, Frédéric Schmidt, Philippe De La Rochere, Nathalie Amzallag, Eduardo Osinaga, Pablo Oppezzo, Otto Pritsch, Xavier Sastre-Garau, Pascale Hubert, Sebastian Amigorena & Eliane Piaggio. (2016) Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen. OncoImmunology 5:7.
Read now
Read now
Erika Vacchelli, Fernando Aranda, Florine Obrist, Alexander Eggermont, Jérôme Galon, Isabelle Cremer, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial watch. OncoImmunology 3:6.
Read now
Read now
T Shantha Raju & William R Strohl. (2013) Potential therapeutic roles for antibody mixtures. Expert Opinion on Biological Therapy 13:10, pages 1347-1352.
Read now
Read now
Articles from other publishers (34)
Hanane Lahnif, Tilmann Grus, Evangelia-Alexandra Salvanou, Elisavet Deligianni, Dimitris Stellas, Penelope Bouziotis & Frank Rösch. (2023) Old Drug, New Delivery Strategy: MMAE Repackaged. International Journal of Molecular Sciences 24:10, pages 8543.
Crossref
Crossref
Avijit Kumar Bakshi, Tanweer Haider, Rahul Tiwari & Vandana Soni. (2022) Critical parameters for design and development of multivalent nanoconstructs: recent trends. Drug Delivery and Translational Research 12:10, pages 2335-2358.
Crossref
Crossref
Md Abdus Subhan & Vladimir P. Torchilin. (2021) Advances with antibody-drug conjugates in breast cancer treatment. European Journal of Pharmaceutics and Biopharmaceutics 169, pages 241-255.
Crossref
Crossref
Andrew P Mayer, Hermes Licea-Perez, Sharon Boram, Kristen E Pannullo, Jonathan Kehler & Christopher A Evans. (2021) Overcoming challenges associated with the bioanalysis of cysteine-conjugated metabolites in the presence of antibody–drug conjugates. Bioanalysis 13:18, pages 1427-1439.
Crossref
Crossref
Amir-Hassan Zarnani, Davood Jafari, Mahmood Bozorgmehr, Mahdi Shabani, Leila Barzegar-Yarmohammadi, Fatemeh Ghaemimanesh & Mahmood Jeddi-Tehrani. 2021. Cancer Immunology. Cancer Immunology
273
312
.
M. Ángeles Rojo, Manuel Garrosa, Pilar Jiménez, Tomás Girbés, Verónica Garcia-Recio, Manuel Cordoba-Diaz & Damián Cordoba-Diaz. (2020) Unexpected Toxicity of Green Tea Polyphenols in Combination with the Sambucus RIL Ebulin. Toxins 12:9, pages 542.
Crossref
Crossref
Jason J. Zoeller, Aleksandr Vagodny, Krishan Taneja, Benjamin Y. Tan, Neil O'Brien, Dennis J. Slamon, Deepak Sampath, Joel D. Leverson, Roderick T. Bronson, Deborah A. Dillon & Joan S. Brugge. (2019)
Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1
In Vivo
. Molecular Cancer Therapeutics 18:6, pages 1115-1126.
Crossref
Crossref
Loganathan Rangasamy, Venkatesh Chelvam, Ananda Kumar Kanduluru, Madduri Srinivasarao, N. Achini Bandara, Fei You, Esteban A. Orellana, Andrea L. Kasinski & Philip S. Low. (2018)
New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K
+
/H
+
Exchange
. Bioconjugate Chemistry 29:4, pages 1047-1059.
Crossref
Crossref
Nimish Gupta, Johny Kancharla, Shelly Kaushik, Aasif Ansari, Samad Hossain, Ravinder Goyal, Manoj Pandey, Jwala Sivaccumar, Sazid Hussain, Arindam Sarkar, Aniruddha Sengupta, Swadhin K. Mandal, Monideepa Roy & Shiladitya Sengupta. (2017) Development of a facile antibody–drug conjugate platform for increased stability and homogeneity. Chemical Science 8:3, pages 2387-2395.
Crossref
Crossref
B. Vijayalakshmi Ayyar, Sushrut Arora & Richard O’Kennedy. (2016) Coming-of-Age of Antibodies in Cancer Therapeutics. Trends in Pharmacological Sciences 37:12, pages 1009-1028.
Crossref
Crossref
Prince Awuah, Tapan K. Bera, Messan Folivi, Oleg Chertov & Ira Pastan. (2016) Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins. Molecular Cancer Therapeutics 15:7, pages 1648-1655.
Crossref
Crossref
Noam Mamet & Ido Bachelet. 2016. Wireless Computing in Medicine. Wireless Computing in Medicine
359
375
.
Yosi Gilad, Michael Firer & Gary Gellerman. (2016) Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells. Biomedicines 4:2, pages 11.
Crossref
Crossref
Veerle Kersemans. 2016. Handbook of Small Animal Imaging. Handbook of Small Animal Imaging
487
508
.
Surjit Dixit. 2015. Developability of Biotherapeutics. Developability of Biotherapeutics
35
60
.
Robert M. Sharkey, William J. McBride, Thomas M. Cardillo, Serengulam V. Govindan, Yang Wang, Edmund A. Rossi, Chien-Hsing Chang & David M. Goldenberg. (2015) Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clinical Cancer Research 21:22, pages 5131-5138.
Crossref
Crossref
Norbert SewaldMichael A Firer & Galia Luboshits. 2015. Optimizing Antibody-Drug Conjugates for Targeted Delivery of Therapeutics. Optimizing Antibody-Drug Conjugates for Targeted Delivery of Therapeutics
106
118
.
Satish K. Singh, Donna L. Luisi & Roger H. Pak. (2015) Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability. Pharmaceutical Research 32:11, pages 3541-3571.
Crossref
Crossref
Boris Redko, Elena Ragozin, Bazylevich Andreii, Tuchinsky Helena, Albeck Amnon, Shekhter Zahavi Talia, Oron-Herman Mor, Kostenich Genady & Gellerman Gary. (2015) Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety. Biopolymers 104:6, pages 743-752.
Crossref
Crossref
David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan, Edmund A. Rossi & Robert M. Sharkey. (2015) Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*. Oncotarget 6:26, pages 22496-22512.
Crossref
Crossref
Hannes Brehm, Dmitrij Hristodorov, Alessa Pardo, Radoslav Mladenov, Judith Niesen, Rainer Fischer, Mehmet K. Tur & Stefan Barth. (2015) Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein. Cancer Letters 365:2, pages 149-155.
Crossref
Crossref
Alison J. Smith. (2015) New Horizons in Therapeutic Antibody Discovery: Opportunities and Challenges versus Small-Molecule Therapeutics. SLAS Discovery 20:4, pages 437-453.
Crossref
Crossref
Amir-Hassan Zarnani, Mahmood Bozorgmehr, Mahdi Shabani, Leila Barzegar-Yarmohammadi, Fatemeh Ghaemimanesh & Mahmood Jeddi-Tehrani. 2015. Cancer Immunology. Cancer Immunology
293
328
.
Ido Bachelet. 2006. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Encyclopedia of Molecular Cell Biology and Molecular Medicine
1
27
.
Yossi Gilad, Michael A. Firer, Alex Rozovsky, Elena Ragozin, Boris Redko, Amnon Albeck & Gary Gellerman. (2014) “Switch off/switch on” regulation of drug cytotoxicity by conjugation to a cell targeting peptide. European Journal of Medicinal Chemistry 85, pages 139-146.
Crossref
Crossref
Qichun Wei, Jing Xu, Li Shen, Xianhua Fu, Bicheng Zhang, Xiaofeng Zhou & Jorgen Carlsson. (2014) HER2 expression in primary gastric cancers and paired synchronous lymph node and liver metastases. A possible road to target HER2 with radionuclides. Tumor Biology 35:7, pages 6319-6326.
Crossref
Crossref
Mojtaba Oraki Kohshour, Sako Mirzaie, Majid Zeinali, Mansour Amin, Mohammad Said Hakhamaneshi, Ali Jalaili, Nader Mosaveri & Mostafa Jamalan. (2014) Ablation of Breast Cancer Cells Using Trastuzumab-Functionalized Multi-Walled Carbon Nanotubes and Trastuzumab-Diphtheria Toxin Conjugate. Chemical Biology & Drug Design 83:3, pages 259-265.
Crossref
Crossref
Serengulam V. Govindan, Thomas M. Cardillo, Robert M. Sharkey, Fatma Tat, David V. Gold & David M. Goldenberg. (2013) Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers. Molecular Cancer Therapeutics 12:6, pages 968-978.
Crossref
Crossref
. (2013) Current World Literature. Current Opinion in Oncology 25:3, pages 325-337.
Crossref
Crossref
Hendrik Fuchs, Christopher Bachran & David Flavell. (2013) Diving through Membranes: Molecular Cunning to Enforce the Endosomal Escape of Antibody-Targeted Anti-Tumor Toxins. Antibodies 2:4, pages 209-235.
Crossref
Crossref
John A. Flygare, Thomas H. Pillow & Paul Aristoff. (2013) Antibody-Drug Conjugates for the Treatment of Cancer. Chemical Biology & Drug Design 81:1, pages 113-121.
Crossref
Crossref
Birte Nolting. 2013. Antibody-Drug Conjugates. Antibody-Drug Conjugates
71
100
.
Michael A Firer & Gary Gellerman. (2012) Targeted drug delivery for cancer therapy: the other side of antibodies. Journal of Hematology & Oncology 5:1.
Crossref
Crossref
Chuda Chittasupho. (2012) Multivalent ligand: design principle for targeted therapeutic delivery approach. Therapeutic Delivery 3:10, pages 1171-1187.
Crossref
Crossref